Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.

ABSTRACT:

Background & aims

Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase and liver histology in non-alcoholic fatty liver disease (NAFLD) patients. We aimed to compare sitagliptin vs. the efficacy of a placebo in reducing liver fat measured by MRI-derived proton density-fat fraction (MRI-PDFF).

Methods

This randomized, double-blind, allocation-concealed, placebo-controlled trial included 50 NAFLD patients with prediabetes or early diabetes randomized to sitagliptin orally 100mg/day or placebo for 24weeks. Primary outcome was liver fat change measured by MRI-PDFF in colocalized regions of interest within each of nine liver segments. Additional advanced assessments included MR spectroscopy (MRS) for internal validation of MRI-PDFF'

SUBMITTER: Cui J 

PROVIDER: S-EPMC5081213 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature